Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs > Silent board

<< Previous

Bullboard Posts

Next >>

Comment by neuralPropheton Mar 01, 2021 12:44pm

381 Views

Post# 32686118

RE:Silent board

Not too may shares outstanding + less than avg 100k shares trading in CanadaUS in total = not enough retail owners to light up a Stockhouse board. Yahoo forum has a bit more action.

Revenue wise, need to wait for FRX to resubmit NDA first to clear up manufacturing concerns, then get regulatory approval.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project